Clinical Trials Browser

Irinotecan × Breast × 1 year × Clear all

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04640480 2026-01-27

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Phase 1/2 Recruiting

10 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT06769425 2025-06-24

HS-10502

Phase 1 Recruiting

157 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT03328884 2025-04-23

Phenomenal

Phase 2 Completed

55 enrolled

Breast

Breast Cancer Metastatic

NCT00576654 2025-04-15

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

73 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Clinical Trials

I-SPY

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

HS-10502

Phenomenal

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery